Education
About Us
Working with TipRanks
Follow Us
Evolus Inc (EOLS)
NASDAQ:EOLS
EOLS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$9.25 - $17.82
Previous CloseN/A
Volume344.54K
Average Volume (3M)856.98K
Market Cap
$908.66M
Enterprise Value$1.07B
Total Cash (Recent Filing)$62.84M
Total Debt (Recent Filing)$126.55M
Price to Earnings (P/E)―
Beta1.37
Next Earnings
May 13, 2025EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.91
Shares Outstanding63,321,490
10 Day Avg. Volume575,174
30 Day Avg. Volume856,975
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.66
Price to Cash Flow (P/CF)-39.70
P/FCF Ratio0.00
Enterprise Value/Market Cap1.18
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit5.86
Enterprise Value/Ebitda-23.78
Forecast
1Y Price Target
$24.80Price Target Upside75.02% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
---
Bulls Say, Bears Say
Bulls Say
Product LaunchThe recently launched Evolysse is expected to contribute 8-10% of total revenue for FY 2025, and the earlier than expected approval gives additional confidence in achieving 2025 numbers.
Revenue GrowthThe 2025 guidance projects 30%-33% year-over-year topline growth, aided by an earlier than expected launch of Evolysse.
Bears Say
Stock VolatilityThe stock experienced a significant drop from $16 down to $10 due to concerns for the 1% change in guidance.
---
Ownership Overview
2.25% Insiders
10.14% Mutual Funds
46.88% Other Institutional Investors
29.74% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
EOLS FAQ
What was Evolus Inc’s price range in the past 12 months?
Evolus Inc lowest stock price was $9.25 and its highest was $17.82 in the past 12 months.
What is Evolus Inc’s market cap?
Evolus Inc’s market cap is $908.66M.
When is Evolus Inc’s upcoming earnings report date?
Evolus Inc’s upcoming earnings report date is May 13, 2025 which is in 67 days.
How were Evolus Inc’s earnings last quarter?
Evolus Inc released its earnings results on Mar 04, 2025. The company reported $0.033 earnings per share for the quarter, beating the consensus estimate of $0.008 by $0.025.
Is Evolus Inc overvalued?
According to Wall Street analysts Evolus Inc’s price is currently Undervalued.
Does Evolus Inc pay dividends?
Evolus Inc does not currently pay dividends.
What is Evolus Inc’s EPS estimate?
Evolus Inc’s EPS estimate is -0.09.
How many shares outstanding does Evolus Inc have?
Evolus Inc has 63,321,490 shares outstanding.
What happened to Evolus Inc’s price movement after its last earnings report?
Evolus Inc reported an EPS of $0.033 in its last earnings report, beating expectations of $0.008. Following the earnings report the stock price went down -1.254%.
Which hedge fund is a major shareholder of Evolus Inc?
Currently, no hedge funds are holding shares in EOLS
---
Evolus Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$24.80 (75.02% Upside)
$24.80 (75.02% Upside)
Blogger Sentiment
Bullish
EOLS Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 620.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 4.6%
Last 30 Days ▼ 6.1%
Last 30 Days ▼ 6.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-2.64%
12-Months-Change
Fundamentals
Return on Equity
-913.07%
Trailing 12-Months
Asset Growth
36.70%
Trailing 12-Months
Company Description
Evolus Inc
Evolus, Inc. is a medical aesthetics company, which engages in the provision of medical aesthetic treatments and procedures. It offers products under the brand of Jeuveau. The company was founded by Scott Cannizzaro in November, 2012 and is headquartered in Newport Beach, CA.
---
EOLS Company Deck
---
EOLS Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Evolus demonstrated strong financial performance with significant revenue growth and profitability achieved ahead of schedule, along with successful product approvals and market expansion. However, there are concerns regarding market conditions and managing cash flow in Q1 2025.Read More>---
EOLS Stock 12 Month Forecast
Average Price Target
$24.80
▲(75.02% Upside)
Technical Analysis
Ironwood Pharma
―
Innoviva
―
Revance Therapeutics
―
Heron Therapeutics
―
Medpace Holdings
―
Best Analysts Covering EOLS
1 Year
1 Year Success Rate
16/21 ratings generated profit
1 Year Average Return
+20.23%
reiterated a buy rating 3 days ago
Copying Uy Ear's trades and holding each position for 1 Year would result in 76.19% of your transactions generating a profit, with an average return of +20.23% per trade.
---